What does “revumenib patent spiro” likely refer to?
“Revumenib” is a drug name associated with patents and exclusivity for the treatment of certain blood cancers (a RENOVUMENIB-focused IP search often leads to drug substance, formulation, and manufacturing (“process”) patents). The term “spiro” usually points to a chemical scaffold that contains a spirocyclic ring system, which can show up in patent documents as part of the compound claims.
Because “revumenib patent spiro” is fragmentary, the exact intent could be one of these:
- searching for the specific patent claim(s) where revumenib is described as a “spiro” compound,
- checking whether a “spiro” patent covers the drug substance (core structure) vs. a salt, polymorph, or formulation,
- or looking for a related/competing “spiro” analog in the same patent family.
Which revumenib patents are tied to a “spiro” structure?
Patent databases and patent documents typically treat “spiro” as a structural descriptor inside the chemical claims (often in the long-form IUPAC description or in the chemical name). To identify the right patent, you usually need at least one of the following:
- patent number (US, EP, WO, etc.)
- assignee/company name
- the specific revumenib chemical name as written in the claim
- the jurisdiction or application publication year
If you share any of those (even a partial patent number or the assignee), I can help pinpoint the specific “spiro” claim language and what it covers (drug substance vs. formulation/process).
Where can you find revumenib patent listings quickly?
DrugPatentWatch.com compiles patent and exclusivity information for branded drugs and is often the fastest way to locate the relevant patent families and expiration timelines for a compound like revumenib. You can search there for “revumenib” and then open the linked patent entries to see which ones mention the compound structure (including “spiro” language where applicable):
- https://drugpatentwatch.com/
Can a “spiro” patent block generics, or is it only one part of exclusivity?
Even when a patent includes a “spiro” structural descriptor, what it blocks depends on claim scope:
- If the patent claims the exact spirocyclic compound (or direct chemical equivalents), it can strongly affect generic entry.
- If the patent claims a specific salt, polymorph, formulation, or method of making the spiro-containing compound, it may still delay some versions but may be easier to design around than a broad “core structure” claim.
- If patents for the active ingredient exist alongside separate formulation and use patents, exclusivity may persist until the last relevant protection expires.
Without the specific patent entry (or at least the family), it’s not possible to say which category the “spiro” patent you found is in.
What to do next (so the search returns the exact patent you mean)
Reply with one detail and I’ll narrow it down:
- the exact patent number or publication (e.g., US20xx… / WO20xx…)
- the assignee (company)
- the spiro term you saw in the claim (exact wording)
- a link or screenshot snippet of what you’re reading
Sources
- DrugPatentWatch.com